Last C$0.83 CAD
Change Today 0.00 / 0.00%
Volume 7.2K
RVX On Other Exchanges
As of 1:14 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

resverlogix corp (RVX) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/3/13 - C$1.16
52 Week Low
08/9/13 - C$0.41
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RESVERLOGIX CORP (RVX)

Related News

No related news articles were found.

resverlogix corp (RVX) Related Businessweek News

No Related Businessweek News Found

resverlogix corp (RVX) Details

Resverlogix Corp., a clinical stage cardiovascular company, develops compounds, which include a therapeutic increase in Apolipoprotein A-I. It primarily develops RVX-208, a small molecule that has completed a Phase IIb clinical trial SUSTAIN and is undergoing a second Phase IIb trial ASSURE for the treatment of atherosclerosis and other chronic diseases, such as neurodegenerative disorders, diabetes mellitus, and Alzheimer's disease. The company is headquartered in Calgary, Canada.

40 Employees
Last Reported Date: 07/26/13

resverlogix corp (RVX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: C$387.1K
Chief Financial Officer
Total Annual Compensation: C$228.0K
Compensation as of Fiscal Year 2013.

resverlogix corp (RVX) Key Developments

Resverlogix Secures an Additional $30 Million from Citibank Loan

Resverlogix Corp. announced that it has entered into an Amended and Restated Loan Agreement with Citibank, N.A. which provides for the existing loan granted to Resverlogix by Citibank to be increased by $30 million to $68.8 million. The loan will be repayable upon maturity on August 28, 2017 and may be prepaid in whole or in part without penalty. Interest on the loan will be payable annually in arrears at a rate equal to the per annum Canadian one-year LIBOR swap rate plus 3.14%, to be reset annually. The loan will be secured by an irrevocable $68.8 million Standby Letter of Credit arranged by Eastern Capital Limited which will be maintained until maturity of the loan. Resverlogix intends to use the net proceeds from the loan to fund clinical trials in targeted high risk patient groups as well as research and development activities, general and administrative expenses and other general corporate purposes. The transaction was unanimously approved by Resverlogix's board of directors.

Resverlogix Corp. Presents at BIO International Convention, Jun-24-2014 02:15 PM

Resverlogix Corp. Presents at BIO International Convention, Jun-24-2014 02:15 PM. Venue: San Diego Convention Center, San Diego, California, United States.

Resverlogix Corp. Presents at BioEquity Europe 2014, May-22-2014 03:00 PM

Resverlogix Corp. Presents at BioEquity Europe 2014, May-22-2014 03:00 PM. Venue: Hilton Amsterdam Hotel, Amsterdam, Netherlands.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RVX:CN C$0.83 CAD 0.00

RVX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RVX.
View Industry Companies

Industry Analysis


Industry Average

Valuation RVX Industry Range
Price/Earnings 1.4x
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow 1.5x
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESVERLOGIX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at